Transdermal Drug Delivery System is a medicated adhesive patch that is placed on the skin to deliver a specific dose of medication through the skin and into the bloodstream. Often, this promotes healing to an injured area of the body. An advantage of a transdermal drug delivery route over other types of medication delivery such as oral, topical, intravenous, intramuscular, etc. is that the patch provides a controlled release of the medication into the patient, usually through either a porous membrane covering a reservoir of medication or through body heat melting thin layers of medication embedded in the adhesive.
麻豆原创 Analysis and Insights: Global Transdermal Drug Delivery System 麻豆原创
The global Transdermal Drug Delivery System market is projected to grow from US$ 17230 million in 2024 to US$ 36450 million by 2030, at a Compound Annual Growth Rate (CAGR) of 13.3% during the forecast period.
Global Transdermal Drug Delivery System key players include Hisamitsu, Mylan, GSK, Novartis, Teve (Actavis), etc. Global top five manufacturers hold a share over 65%. North America is the largest market, with a share over 40%, followed by Europe and Asia-Pacific, both have a share over 45% percent.
In terms of product, Nitroglycerin is the largest segment, with a share over 25%. And in terms of application, the largest application is OTC, followed by RX.
Report Covers:
This report presents an overview of global market for Transdermal Drug Delivery System market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Transdermal Drug Delivery System, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Transdermal Drug Delivery System, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Transdermal Drug Delivery System revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Transdermal Drug Delivery System market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Transdermal Drug Delivery System revenue, projected growth trends, production technology, application and end-user industry.
麻豆原创 Segmentation
By Company
Hisamitsu
Mylan
GSK
Novartis
Teve (Actavis)
Johnson & Johnson
Lohmann
Teikoku Seiyaku
Bayer
Lingrui
Sanofi
Qizheng
Endo
Huarun 999
Haw Par
Nichiban
Mentholatum
Laboratoires Genevrier
Segment by Type
Fentanyl
Nitroglycerin
Estradiol
Nicotine
Other
Segment by Application
OTC
Rx
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Transdermal Drug Delivery System in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Transdermal Drug Delivery System companies鈥� competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Transdermal Drug Delivery System revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Transdermal Drug Delivery System 麻豆原创 Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Fentanyl
1.2.3 Nitroglycerin
1.2.4 Estradiol
1.2.5 Nicotine
1.2.6 Other
1.3 麻豆原创 by Application
1.3.1 Global Transdermal Drug Delivery System 麻豆原创 Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 OTC
1.3.3 Rx
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Transdermal Drug Delivery System 麻豆原创 Perspective (2019-2030)
2.2 Global Transdermal Drug Delivery System Growth Trends by Region
2.2.1 Transdermal Drug Delivery System 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Transdermal Drug Delivery System Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Transdermal Drug Delivery System Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Transdermal Drug Delivery System 麻豆原创 Dynamics
2.3.1 Transdermal Drug Delivery System Industry Trends
2.3.2 Transdermal Drug Delivery System 麻豆原创 Drivers
2.3.3 Transdermal Drug Delivery System 麻豆原创 Challenges
2.3.4 Transdermal Drug Delivery System 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Transdermal Drug Delivery System by Players
3.1.1 Global Transdermal Drug Delivery System Revenue by Players (2019-2024)
3.1.2 Global Transdermal Drug Delivery System Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Transdermal Drug Delivery System 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Transdermal Drug Delivery System, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Transdermal Drug Delivery System 麻豆原创 Concentration Ratio
3.4.1 Global Transdermal Drug Delivery System 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Transdermal Drug Delivery System Revenue in 2023
3.5 Global Key Players of Transdermal Drug Delivery System Head office and Area Served
3.6 Global Key Players of Transdermal Drug Delivery System, Product and Application
3.7 Global Key Players of Transdermal Drug Delivery System, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Transdermal Drug Delivery System Breakdown Data by Type
4.1 Global Transdermal Drug Delivery System Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Transdermal Drug Delivery System Forecasted 麻豆原创 Size by Type (2025-2030)
5 Transdermal Drug Delivery System Breakdown Data by Application
5.1 Global Transdermal Drug Delivery System Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Transdermal Drug Delivery System Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Transdermal Drug Delivery System 麻豆原创 Size (2019-2030)
6.2 North America Transdermal Drug Delivery System 麻豆原创 Size by Type
6.2.1 North America Transdermal Drug Delivery System 麻豆原创 Size by Type (2019-2024)
6.2.2 North America Transdermal Drug Delivery System 麻豆原创 Size by Type (2025-2030)
6.2.3 North America Transdermal Drug Delivery System 麻豆原创 Share by Type (2019-2030)
6.3 North America Transdermal Drug Delivery System 麻豆原创 Size by Application
6.3.1 North America Transdermal Drug Delivery System 麻豆原创 Size by Application (2019-2024)
6.3.2 North America Transdermal Drug Delivery System 麻豆原创 Size by Application (2025-2030)
6.3.3 North America Transdermal Drug Delivery System 麻豆原创 Share by Application (2019-2030)
6.4 North America Transdermal Drug Delivery System 麻豆原创 Size by Country
6.4.1 North America Transdermal Drug Delivery System 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Transdermal Drug Delivery System 麻豆原创 Size by Country (2019-2024)
6.4.3 North America Transdermal Drug Delivery System 麻豆原创 Size by Country (2025-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Transdermal Drug Delivery System 麻豆原创 Size (2019-2030)
7.2 Europe Transdermal Drug Delivery System 麻豆原创 Size by Type
7.2.1 Europe Transdermal Drug Delivery System 麻豆原创 Size by Type (2019-2024)
7.2.2 Europe Transdermal Drug Delivery System 麻豆原创 Size by Type (2025-2030)
7.2.3 Europe Transdermal Drug Delivery System 麻豆原创 Share by Type (2019-2030)
7.3 Europe Transdermal Drug Delivery System 麻豆原创 Size by Application
7.3.1 Europe Transdermal Drug Delivery System 麻豆原创 Size by Application (2019-2024)
7.3.2 Europe Transdermal Drug Delivery System 麻豆原创 Size by Application (2025-2030)
7.3.3 Europe Transdermal Drug Delivery System 麻豆原创 Share by Application (2019-2030)
7.4 Europe Transdermal Drug Delivery System 麻豆原创 Size by Country
7.4.1 Europe Transdermal Drug Delivery System 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Transdermal Drug Delivery System 麻豆原创 Size by Country (2019-2024)
7.4.3 Europe Transdermal Drug Delivery System 麻豆原创 Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Transdermal Drug Delivery System 麻豆原创 Size (2019-2030)
8.2 China Transdermal Drug Delivery System 麻豆原创 Size by Type
8.2.1 China Transdermal Drug Delivery System 麻豆原创 Size by Type (2019-2024)
8.2.2 China Transdermal Drug Delivery System 麻豆原创 Size by Type (2025-2030)
8.2.3 China Transdermal Drug Delivery System 麻豆原创 Share by Type (2019-2030)
8.3 China Transdermal Drug Delivery System 麻豆原创 Size by Application
8.3.1 China Transdermal Drug Delivery System 麻豆原创 Size by Application (2019-2024)
8.3.2 China Transdermal Drug Delivery System 麻豆原创 Size by Application (2025-2030)
8.3.3 China Transdermal Drug Delivery System 麻豆原创 Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Transdermal Drug Delivery System 麻豆原创 Size (2019-2030)
9.2 Asia Transdermal Drug Delivery System 麻豆原创 Size by Type
9.2.1 Asia Transdermal Drug Delivery System 麻豆原创 Size by Type (2019-2024)
9.2.2 Asia Transdermal Drug Delivery System 麻豆原创 Size by Type (2025-2030)
9.2.3 Asia Transdermal Drug Delivery System 麻豆原创 Share by Type (2019-2030)
9.3 Asia Transdermal Drug Delivery System 麻豆原创 Size by Application
9.3.1 Asia Transdermal Drug Delivery System 麻豆原创 Size by Application (2019-2024)
9.3.2 Asia Transdermal Drug Delivery System 麻豆原创 Size by Application (2025-2030)
9.3.3 Asia Transdermal Drug Delivery System 麻豆原创 Share by Application (2019-2030)
9.4 Asia Transdermal Drug Delivery System 麻豆原创 Size by Region
9.4.1 Asia Transdermal Drug Delivery System 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Transdermal Drug Delivery System 麻豆原创 Size by Region (2019-2024)
9.4.3 Asia Transdermal Drug Delivery System 麻豆原创 Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Transdermal Drug Delivery System 麻豆原创 Size (2019-2030)
10.2 Middle East, Africa, and Latin America Transdermal Drug Delivery System 麻豆原创 Size by Type
10.2.1 Middle East, Africa, and Latin America Transdermal Drug Delivery System 麻豆原创 Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Transdermal Drug Delivery System 麻豆原创 Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Transdermal Drug Delivery System 麻豆原创 Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Transdermal Drug Delivery System 麻豆原创 Size by Application
10.3.1 Middle East, Africa, and Latin America Transdermal Drug Delivery System 麻豆原创 Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Transdermal Drug Delivery System 麻豆原创 Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Transdermal Drug Delivery System 麻豆原创 Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Transdermal Drug Delivery System 麻豆原创 Size by Country
10.4.1 Middle East, Africa, and Latin America Transdermal Drug Delivery System 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Transdermal Drug Delivery System 麻豆原创 Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Transdermal Drug Delivery System 麻豆原创 Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Hisamitsu
11.1.1 Hisamitsu Company Details
11.1.2 Hisamitsu Business Overview
11.1.3 Hisamitsu Transdermal Drug Delivery System Introduction
11.1.4 Hisamitsu Revenue in Transdermal Drug Delivery System Business (2019-2024)
11.1.5 Hisamitsu Recent Developments
11.2 Mylan
11.2.1 Mylan Company Details
11.2.2 Mylan Business Overview
11.2.3 Mylan Transdermal Drug Delivery System Introduction
11.2.4 Mylan Revenue in Transdermal Drug Delivery System Business (2019-2024)
11.2.5 Mylan Recent Developments
11.3 GSK
11.3.1 GSK Company Details
11.3.2 GSK Business Overview
11.3.3 GSK Transdermal Drug Delivery System Introduction
11.3.4 GSK Revenue in Transdermal Drug Delivery System Business (2019-2024)
11.3.5 GSK Recent Developments
11.4 Novartis
11.4.1 Novartis Company Details
11.4.2 Novartis Business Overview
11.4.3 Novartis Transdermal Drug Delivery System Introduction
11.4.4 Novartis Revenue in Transdermal Drug Delivery System Business (2019-2024)
11.4.5 Novartis Recent Developments
11.5 Teve (Actavis)
11.5.1 Teve (Actavis) Company Details
11.5.2 Teve (Actavis) Business Overview
11.5.3 Teve (Actavis) Transdermal Drug Delivery System Introduction
11.5.4 Teve (Actavis) Revenue in Transdermal Drug Delivery System Business (2019-2024)
11.5.5 Teve (Actavis) Recent Developments
11.6 Johnson & Johnson
11.6.1 Johnson & Johnson Company Details
11.6.2 Johnson & Johnson Business Overview
11.6.3 Johnson & Johnson Transdermal Drug Delivery System Introduction
11.6.4 Johnson & Johnson Revenue in Transdermal Drug Delivery System Business (2019-2024)
11.6.5 Johnson & Johnson Recent Developments
11.7 Lohmann
11.7.1 Lohmann Company Details
11.7.2 Lohmann Business Overview
11.7.3 Lohmann Transdermal Drug Delivery System Introduction
11.7.4 Lohmann Revenue in Transdermal Drug Delivery System Business (2019-2024)
11.7.5 Lohmann Recent Developments
11.8 Teikoku Seiyaku
11.8.1 Teikoku Seiyaku Company Details
11.8.2 Teikoku Seiyaku Business Overview
11.8.3 Teikoku Seiyaku Transdermal Drug Delivery System Introduction
11.8.4 Teikoku Seiyaku Revenue in Transdermal Drug Delivery System Business (2019-2024)
11.8.5 Teikoku Seiyaku Recent Developments
11.9 Bayer
11.9.1 Bayer Company Details
11.9.2 Bayer Business Overview
11.9.3 Bayer Transdermal Drug Delivery System Introduction
11.9.4 Bayer Revenue in Transdermal Drug Delivery System Business (2019-2024)
11.9.5 Bayer Recent Developments
11.10 Lingrui
11.10.1 Lingrui Company Details
11.10.2 Lingrui Business Overview
11.10.3 Lingrui Transdermal Drug Delivery System Introduction
11.10.4 Lingrui Revenue in Transdermal Drug Delivery System Business (2019-2024)
11.10.5 Lingrui Recent Developments
11.11 Sanofi
11.11.1 Sanofi Company Details
11.11.2 Sanofi Business Overview
11.11.3 Sanofi Transdermal Drug Delivery System Introduction
11.11.4 Sanofi Revenue in Transdermal Drug Delivery System Business (2019-2024)
11.11.5 Sanofi Recent Developments
11.12 Qizheng
11.12.1 Qizheng Company Details
11.12.2 Qizheng Business Overview
11.12.3 Qizheng Transdermal Drug Delivery System Introduction
11.12.4 Qizheng Revenue in Transdermal Drug Delivery System Business (2019-2024)
11.12.5 Qizheng Recent Developments
11.13 Endo
11.13.1 Endo Company Details
11.13.2 Endo Business Overview
11.13.3 Endo Transdermal Drug Delivery System Introduction
11.13.4 Endo Revenue in Transdermal Drug Delivery System Business (2019-2024)
11.13.5 Endo Recent Developments
11.14 Huarun 999
11.14.1 Huarun 999 Company Details
11.14.2 Huarun 999 Business Overview
11.14.3 Huarun 999 Transdermal Drug Delivery System Introduction
11.14.4 Huarun 999 Revenue in Transdermal Drug Delivery System Business (2019-2024)
11.14.5 Huarun 999 Recent Developments
11.15 Haw Par
11.15.1 Haw Par Company Details
11.15.2 Haw Par Business Overview
11.15.3 Haw Par Transdermal Drug Delivery System Introduction
11.15.4 Haw Par Revenue in Transdermal Drug Delivery System Business (2019-2024)
11.15.5 Haw Par Recent Developments
11.16 Nichiban
11.16.1 Nichiban Company Details
11.16.2 Nichiban Business Overview
11.16.3 Nichiban Transdermal Drug Delivery System Introduction
11.16.4 Nichiban Revenue in Transdermal Drug Delivery System Business (2019-2024)
11.16.5 Nichiban Recent Developments
11.17 Mentholatum
11.17.1 Mentholatum Company Details
11.17.2 Mentholatum Business Overview
11.17.3 Mentholatum Transdermal Drug Delivery System Introduction
11.17.4 Mentholatum Revenue in Transdermal Drug Delivery System Business (2019-2024)
11.17.5 Mentholatum Recent Developments
11.18 Laboratoires Genevrier
11.18.1 Laboratoires Genevrier Company Details
11.18.2 Laboratoires Genevrier Business Overview
11.18.3 Laboratoires Genevrier Transdermal Drug Delivery System Introduction
11.18.4 Laboratoires Genevrier Revenue in Transdermal Drug Delivery System Business (2019-2024)
11.18.5 Laboratoires Genevrier Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Hisamitsu
Mylan
GSK
Novartis
Teve (Actavis)
Johnson & Johnson
Lohmann
Teikoku Seiyaku
Bayer
Lingrui
Sanofi
Qizheng
Endo
Huarun 999
Haw Par
Nichiban
Mentholatum
Laboratoires Genevrier
听
听
*If Applicable.
